AM/PM dosing of LAMA for COPD: a randomized controlled trial protocol using digital recruitment and registries

RationaleLong-acting muscarinic antagonists (LAMAs) reduce the risk of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), usually taken once daily in the morning. However, the circadian activity of autonomic regulation suggests that the highest need for anticholinergic therapy ma...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Pradeesh Sivapalan, Valdemar Rømer, Tobias Wirenfeldt Klausen, Niklas Dyrby Johansen, Manan Pareek, Daniel Modin, Alexander Mathioudakis, Jørgen Vestbo, Josefin Eklöf, Alexander Jordan, John R. Hurst, Tor Biering-Sørensen, Jens-Ulrik Jensen
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2024-08-01
Σειρά:	Frontiers in Medicine
Θέματα:	long-acting muscarinic antagonists chronic obstructive pulmonary disease COPD exacerbation all-cause mortality intensive care admission
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fmed.2024.1430169/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!